Meeting
2018 ASCO Annual Meeting
A multicentric single-arm phase II clinical trial to evaluate safety and efficacy of the combination of olaparib and PLD for platinum resistant ovarian primary peritoneal carcinoma and fallopian tube cancer patients: The GEICO-1601 ROLANDO trial—A trial in resistant ovarian cancer with olaparib and pegylated liposomal doxorubicin.
Authors
Jose Alejandro Perez-Fidalgo
Hospital Clínico Universitario de Valencia; INCLIVA; Centro de Investigación Biomédica en Red de Oncología; CIBERONC-ISCIII; GEICAM Spanish Breast Cancer Group, Valencia, Spain
Jose Alejandro Perez-Fidalgo , Uriel Bohn , Elisa Calvo , Yolanda Garcia Garcia , Eva Mª Guerra , Maria Iglesias , Luis Manso , Ana Santaballa , Antonio González-Martín
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT03161132
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS5610)
DOI
10.1200/JCO.2018.36.15_suppl.TPS5610
Abstract #
TPS5610
Poster Bd #
332a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
First Author: Kathleen N. Moore
Poster
2021 ASCO Annual Meeting
Health-related quality of life (QoL) in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD), a multicenter single-arm phase II clinical trial (ROLANDO, GEICO-1601).
First Author: José Alejandro Perez-Fidalgo
Poster
2021 ASCO Annual Meeting
Niraparib efficacy and safety in patients with BRCA mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials.
First Author: Antonio Gonzalez Martin
First Author: Sergei Tjulandin